Biocept Q1 Revenues Rise With Test Volume Growth | GenomeWeb

NEW YORK (GenomeWeb) - Biocept reported today after the close of the market that its first quarter revenues rose to $150,000 compared to $28,000 in Q1 2014, with the increase primarily due to growing commercial liquid biopsy test volumes.

The San Diego-based firm, which sells molecular diagnostic tests based on circulating tumor cells and circulating tumor DNA, said it tested 247 commercial cases during the first quarter of 2015, up from 11 commercial cases during the first quarter of 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.